World Premiere of confident brand ambassador / Spectacular Reveal of Striking Opel GTC Concept
more
Stories about Business
Merlin Entertainments Group Deutschland
The Perfect Combination - Merlin and Tussauds - Creating the World's No 2 Visitor Attraction Company - With Photo
London, New York and Dubai (ots) - Merlin Entertainments Group ("Merlin"), controlled by the Blackstone Group ("Blackstone"), and The Tussauds Group ("TTG"), controlled by Dubai International Capital LLC ("DIC"), are today announcing a partnership of two rapidly growing businesses. This brings together ...
moreData Published in AIDS Show Viramune(R) (nevirapine) Achieves Durable Benefit in Switch Patients
Ingelheim, Germany (ots/PRNewswire) - Long-term data from the Nevirapine/Efavirenz/Abacavir (NEFA) study demonstrate that patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen containing Viramune(R) (nevirapine) or efavirenz achieved comparable efficacy and safety to their previous regimen ...
moreLong-Term Data Show Aptivus(R) (tipranavir) Continues to Outperform Group of Protease Inhibitors in RESIST Trials
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
moreFDA Approves Boehringer Ingelheim's Pramipexole for the Treatment of Moderate-to-Severe Primary Restless Legs Syndrome (RLS)
Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...
moreBoehringer Ingelheim's Pramipexole (Mirapexin(R)/Sifrol(R)) Shown to Improve Depressive and Motivational Symptoms in Parkinson's Disease
Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
moreBoehringer Ingelheim: Unfounded Fear of Addiction Prevents Laxative Use
Berlin, Germany (ots/PRNewswire) - - Global Survey Highlights Misunderstandings About Causes and Treatment of Constipation - Not for use or publication in the USA Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show ...
moreTipranavir Achieves Virologic and Immunologic Improvements in HIV-Positive Children at 48-Weeks of Therapy
Toronto (ots/PRNewswire) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were announced today at the 16th International AIDS Conference (IAC) in Toronto, Canada. Results from this 48-week analysis show that patients achieved virologic ...
moreBASF Completes Acquisition of Engelhard Corporation
Ludwigshafen, Germany (ots/PRNewswire) - - BASF CEO Hambrecht: 'We started the integration process.' BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced the successful completion of its acquisition of Engelhard Corporation (NYSE: EC). "Together with the Engelhard team we have started the integration process in which our customers continue to be the key priority," ...
moreBASF Receives Over 90% of Engelhard Shares
Ludwigshafen, Germany (ots/PRNewswire) - - BASF Announces Completion of Subsequent Offering Period BASF Aktiengesellschaft (Frankfurt: BAS; NYSE: BF [ADR]; LSE: BFA; SWX: AN) today announced the completion of the subsequent offering period for the outstanding shares of Engelhard. As of 8:00 p.m. New York City time on June 8, 2006, a total of 113,489,680 shares, representing more than 90% of Engelhard's (NYSE: ...
moreBASF Receives Majority of Engelhard Shares
Ludwigshafen, Germany (ots/PRNewswire) - - BASF-CEO Hambrecht: 'Special day for BASF and Engelhard, more innovative solutions for customers.' - Subsequent offering period to expire on June 8, 2006 BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced the expiration of its initial tender offer period to purchase all of the outstanding shares of Engelhard Corporation ...
moreBASF and Engelhard Reach Agreement
Ludwigshafen, Germany (ots/PRNewswire) - - Engelhard Recommends That Engelhard's Shareholders Accept BASF's Offer - BASF CEO Hambrecht: "Crucial step towards acquisition of Engelhard." BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) announced today that it signed a definitive agreement with Engelhard Corporation (NYSE: EC). According to the agreement, Engelhard will recommend that Engelhard shareholders tender their shares to BASF ...
moreNew Data Shed Light on the Global Incidence of Constipation
Ingelheim, Germany (ots/PRNewswire) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in Los Angeles. The survey, sponsored by Boehringer Ingelheim, offers new insights into the incidence of constipation and shows that ...
moreNew Evidence Validates Global Prevalence and Severity of Abdominal Cramping and Pain
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25% of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international gastroenterology congress Digestive Disease Week (DDW) 2006 ...
moreBASF Considers All Options
Ludwigshafen, Germany (ots/PRNewswire) - - BASF's All-Cash Bid Provides Greater Value and Certainty than Engelhard's Proposal BASF is considering all its options after Engelhard's Board of Directors rejected an increased cash offer of US$38 per share proposed by BASF, as part of a negotiated merger transaction, and elected instead to pursue a partial share buyback plan. Following a preliminary review of Engelhard's proposed transaction, BASF continues to ...
moreNot only for medical purposes: Computer tomography improves industrial production
Hanover (ots) - Hanover Fair Hall 17, Stand B76 3D inspection of electronic components - more safety, lower recall rate, less reject due to defects - Viscom anticipates a market potential worth millions. Established already in medicine, the computer tomography (CT) swiftly conquers the realm of industrial production. Some of the benefits for manufacturers and ...
moreViscom AG Strives for Initial Opening in May
Hanover (ots) - Hanover Fair Hall 17, Stand B76 Stock exchange plans solidified - transaction volume of from 40 to 60 million euros - 80 percent of the capital to flow back into the company The Viscom AG, supplier of automatic optical inspection systems for the electronics industry, solidifies their stock exchange plans: the initial listing in the Prime Standard of the Frankfurt Stock Exchange shall take ...
moreTop quality - Viscom introduces the S3012ROB system for inspection of complex 3D objects
Hanover (ots) - Hanover Fair, Hall 17, Stand B76 At the Hanover Fair 2006 Viscom introduces the robot-supported inspection system S3012ROB. This robot allows for a best quality assurance while inspecting complex 3D objects. A complete inspection of assembled or processed objects is a core part of the quality assurance process in modern industry. ...
moreBASF Extends US$37 Cash Tender Offer to April 28, 2006
Ludwigshafen, Germany (ots/PRNewswire) - BASF Aktiengesellschaft (Frankfurt: BAS; NYSE: BF [ADR]; LSE: BFA; SWX: AN) today announced that, through its wholly owned subsidiary, Iron Acquisition Corporation, it has extended the expiration date of its US$37 cash tender offer for all of the issued and outstanding shares of common stock of Engelhard Corporation (NYSE: EC) to 5:00 p.m., New York City time, on Friday, ...
moreASSB in Malaysia celebrates Ground Breaking - Operations start 2007
moreBoehringer Ingelheim Receives Recommendation From EU Scientific Committee for Sifrol(R)/ Mirapexin(R) (Pramipexole) for the Treatment of Restless Legs Syndrome (RLS)
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Professional Media Boehringer Ingelheim announced today that that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Sifrol(R) / Mirapexin(R) ...
moresecunet offers a glimpse of the future - Essen-based security company presents wide range of services and products at the CeBIT
Essen/Germany (ots) - At this year's CeBIT, secunet Security Networks AG is presenting established high-security products and services, current developments and research into the future of IT security. The company focuses on high-security communication possibilities, efficient use of biometrics and secure ...
moreNew Data Confirm Pramipexole Delivers Sustained Efficacy For Patients With Restless Legs Syndrome
Berlin, Germany (ots/PRNewswire) - - For Healthcare Professional Journalists - Not for distribution to US media - Randomised, Placebo-Controlled Study Shows Discontinuation of Pramipexole Leads to Rapid Worsening of Symptoms - Two new, randomised, placebo-controlled studies presented this week at the ...
morePositive Opinion in Europe for Tipranavir
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...
moreU.S. FDA Approves New Anti-HIV Drug Aptivus(R) for Use in Combination Therapy
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
moreSharp Electronics (Europe) GmbH
Double the Business!
Hamburg, Germany (ots) - - cross-reference: The detailled version of the press release is available under http://www.presseportal.de/dokumente.html - Sharp Electronics Europe CEO Hans Kleis wants to double the turnover of the Japanese technology group in Europe by the end of fiscal year 2007 by focusing on the three strategic divisions of LCD TV, Document Solutions and ...
One documentmoreFord And PSA Peugeot Citroën Announce Plans For Expansion Of Diesel Engine Production
Cologne, Germany (ots) - Ford Motor Company and PSA Peugeot Citroën are planning to expand production capacity for the 1.4, 1.6 and 2.0 litre high technology diesel engines from the ongoing cooperative agreement between the two companies. This cooperative agreement is enabling both companies to be world leaders in diesel engineering and manufacture and to ...
moreBoehringer Ingelheim Announces 24-Week Results From Second Phase III Pivotal Study of Tipranavir
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
moreBoehringer Ingelheim Announces 24-Week Interim Results from Tipranavir RESIST-1 Phase 3 Study
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
moreBoehringer Ingelheim Submits Marketing Authorisation Application to European Union and to the FDA for Investigational Anti-HIV Agent Tipranavir
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...
more
Previous69707172737475767778Next